Long-time collaborators Biogen, Inc. and Ionis Pharmaceuticals, Inc. announced updates for two programs in mid-stage clinical development on 16 May, reporting that they will end development of BIIB105 after the drug failed in a Phase I/II clinical trial in amyotrophic lateral sclerosis (ALS). Ionis also revealed updated results from a Phase I/IIa trial of ION582 (BIIB121) in Angelman syndrome and said it will take the drug into Phase III on its own after Biogen opted out of the program.
Key Takeaways
-
Biogen and Ionis will discontinue development of BIIB105 for ALS after the drug failed to provide clinical benefit in a Phase I/II study.
Both companies traded lower on the updates, with Biogen closing down 2.2% at $230.04 per share and Ionis ending the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)